Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
You may also be interested in...
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.